Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova最新文献

{"title":"[Sleep disorders in patients with medication-overuse headache].","authors":"I A Kniazeva, D V Gilev, E R Lebedeva","doi":"10.17116/jnevro202412405293","DOIUrl":"https://doi.org/10.17116/jnevro202412405293","url":null,"abstract":"<p><strong>Objective: </strong>To analyze complaints about sleep disorders and assess the incidence of various sleep disorders, using relevant scales, in patients with medication-overuse headache (MOH) in comparison with patients without MOH.</p><p><strong>Material and methods: </strong>The prospective case-control study included 171 patients, aged 18 years and older, with MOH (main group), and173 patients with primary headaches without MOH (control group). A neurologist conducted an initial examination and professional interview before the start of treatment. To diagnose sleep disorders, the International Classification of Sleep Disorders (3rd edition, 2014) was used. Additionally, an assessment was made using the Insomnia Severity Index Scale, the Epworth Sleepiness Scale (ESS) and the Lausanne Obstructive Sleep Apnea Syndrome Scale (NoSAS).</p><p><strong>Results: </strong>Statistically significant differences were revealed in the prevalence of the following complaints about sleep disorders in patients with MOH: lack of sleep (51.5%), frequent awakenings during sleep (43.3%), discomfort in legs before falling asleep or at rest in the evening (37.4%). Difficulties falling asleep occurred equally often in both patients with MOH (43.9%) and without MOH (37.0%), as well as daytime sleepiness (40.4% vs 36.4%) and the presence of snoring (13% of patients in each group). Patients with MOH were significantly more likely to suffer from chronic insomnia (60.2% and 47.4%, respectively, <i>p</i>=0.02; OR 1.7; 95% CI 1.1-2.6) and restless legs syndrome (37.4% and 22.0%, respectively, <i>p</i>=0.002; OR 2.1; 95% CI 1.3-3.4). The incidence of hypersomnia and obstructive sleep apnea syndrome did not have statistically significant differences.</p><p><strong>Conclusion: </strong>Patients with MOH compared to patients without MOH have a significantly higher incidence of main complaints of sleep disorders, chronic insomnia and restless legs syndrome, which indicates the importance of sleep disorders in the pathogenesis of medication-overuse headaches and requires timely diagnosis and treatment to prevent the progression of both headaches and sleep disorders.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"124 5. Vyp. 2","pages":"93-98"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141461116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Features of course of pain syndrome in patients with schwannomatosis].","authors":"E S Makashova, A G Voloshin, S V Zolotova, V V Strelnikov, A V Golanov","doi":"10.17116/jnevro202412405148","DOIUrl":"https://doi.org/10.17116/jnevro202412405148","url":null,"abstract":"<p><strong>Objective: </strong>To identify the characteristics of pain syndrome in patients with schwannomas depending on genetic predisposition.</p><p><strong>Material and methods: </strong>The study included 46 patients with peripheral, spinal and intracranial schwannomas, corresponding to the schwannomatosis phenotype according to the 2022 clinical criteria. All patients underwent sequencing of the <i>LZRT1</i>, <i>Nf2</i> and <i>SMARCB1</i> and a copy number study in the <i>NF2</i>.</p><p><strong>Results: </strong>The most severe widespread pain was observed in patients with pathogenic <i>LZRT1</i> variants, while patients with mosaic variants may not even have local tumor-related pain. Patients with <i>SMARCB1</i>variants may have no pain or have localized pain that responds well to surgical treatment.</p><p><strong>Conclusion: </strong>Further studies of the molecular features of schwannomatosis and driver mutations in the pathogenesis of pain are necessary to improve the effectiveness of pain therapy in this group of patients. Schwannomatosis is a disease from the group of neurofibromatosis, manifested by the development of multiple schwannomas. Neuropathic pain is one of the main symptoms characteristic of peripheral schwannomas, however, the severity and prevalence of the pain syndrome does not always correlate with the location of the tumors. According to modern concepts, the key factors influencing the characteristics of the pain syndrome are the target gene and the type of pathogenic variant. The most severe widespread pain is observed in patients with pathogenic variants in the LZRT1 gene, while patients with mosaic variants may not even have local pain associated with tumors. Patients with variants in SMARCB1 may have no pain or localized pain that responds well to surgical treatment.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"124 5","pages":"48-52"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141332550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Anxiety disorders as comorbid conditions in neuropsychiatric diseases in children].","authors":"N N Zavadenko, Yu E Nesterovskiy, A N Zavadenko, E M Shypilova","doi":"10.17116/jnevro202412407156","DOIUrl":"https://doi.org/10.17116/jnevro202412407156","url":null,"abstract":"<p><p>The variants of heterotypic comorbidity of anxiety disorders (AD) with attention deficit hyperactivity disorder, autism spectrum disorders, speech and language development disorders, specific learning disabilities (dyslexia, dysgraphia, dyscalculia), migraine, tension type headache in children and adolescents are discussed. In cases of heterotypic comorbidity the patients with AD referrals to specialists may be primarily associated with their emotional problems. Meanwhile, the comorbidity of AD with these diseases leads to a deterioration of their clinical manifestations and a worsening of the prognosis, and anxiety symptoms often not only persist, but also increase with age. It should be borne in mind that AD in children with neurodevelopmental disorders contribute to a decrease in the quality of life, academic failure, have a negative impact on peer relationships and the family environment, and in young adulthood, patients have an increased risk of depression and substance abuse. Therefore, early intervention and a comprehensive therapeutic approach with a dynamic assessment of the patient's condition are becoming important. When choosing pharmacotherapy, it is advisable to choose medictions that have a complex effect on the pathogenetic mechanisms of the underlying disease and concomitant AD, which include Tenoten for children.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"124 7","pages":"56-64"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Russian adaptation of the Clinical Perfectionism Questionnaire].","authors":"A M Skupova, I S Turkina, M S Aslanova, U A Nikolkina","doi":"10.17116/jnevro2024124071112","DOIUrl":"https://doi.org/10.17116/jnevro2024124071112","url":null,"abstract":"<p><strong>Objective: </strong>Adaptation of the Russian version of the Clinical Perfectionist Questionnaire (CPQ, Fairburn, Cooper, Shafran 2002) and evaluation of its psychometric features.</p><p><strong>Material and methods: </strong>One hundred and thirty-five people (98 (72.6%) women, 37 (27.4%) men) at the age from 18 to 36 (M=25.10; SD=4.92) took part in this study. Fifty-seven participants are diagnosed with eating disorder. Respondents completed the adapted version of CPQ, The Eating Attitudes Test (EAT-26) (Skugarevsky and Sivuha adaptation) and the Three-factor perfectionism questionnaire (Garanyan, Holmogorova).</p><p><strong>Results: </strong>Three-factor structure was found from 12 questions of CPQ: self-esteem based on achievements; correspondence with high standards; negative evaluation of results. Inner coherence of the factors is high and acceptable (Cronbachs alpha 0.784, 0.691 and 0.609, respectively). There are statistically significant positive correlations between scales of CPQ and scales of the Three-factor perfectionism questionnaire. There is a significant positive correlation between CPQ scale «self-esteem based on achievements» and summed result of EAT-26 (<i>p<</i>0.05). No significant differences in results of each CPQ scale between people with- and without diagnosed eating disorder is found.</p><p><strong>Conclusion: </strong>The adapted Russian version of CPQ showed relevant psychometric characteristics, therefore it may be used as an additional instrument for diagnosing of eating desorders.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"124 7","pages":"112-118"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Pharmacotherapy of schizophrenia: clinical and some age-related aspects].","authors":"S V Ivanov, A V Goryunov","doi":"10.17116/jnevro202412407141","DOIUrl":"https://doi.org/10.17116/jnevro202412407141","url":null,"abstract":"<p><p>The article discusses modern approaches to the rational choice of therapy for schizophrenia in accordance with the principles of personalized medicine. Clinical markers for determining the optimal treatment tactics are considered depending on the syndromic features and stereotype of the course of the disease, and the possibility of justified combination therapy with drugs of different pharmacological classes. The specifics of the treatment of schizophrenia in childhood/adolescence and adult are discussed, including the basic principles of choosing drug classes, daily doses and drug therapy tactics.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"124 7","pages":"41-50"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical anatomy of the Bernasconi-Cassinari artery].","authors":"S A Kutia, O Ya Yarovaya, E V Kuznetsova, D D Obukhova, V I Kuznetsov","doi":"10.17116/jnevro202412403212","DOIUrl":"10.17116/jnevro202412403212","url":null,"abstract":"<p><p>The article provides a comprehensive overview of the Bernasconi-Cassinari's artery (marginal tentorial branch of internal carotid artery, <i>r. marginalis tentorii a. carotis internae</i>). It includes information on the history of its discovery, anatomical features, and topography. The interrelation between the anatomical features of this artery and the presence of neurological pathology in patients is discussed, along with neurosurgical treatment methodologies.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"124 3. Vyp. 2","pages":"12-17"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140177933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The secretome of mesenchymal stromal cells as a new hope in the treatment of acute brain tissue injuries].","authors":"A L Primak, M N Skryabina, S S Dzhauari, V A Tkachuk, M N Karagyaur","doi":"10.17116/jnevro202412403283","DOIUrl":"10.17116/jnevro202412403283","url":null,"abstract":"<p><p>Ischemic and hemorrhagic strokes, traumatic brain injury, bacterial and viral encephalitis, toxic and metabolic encephalopathies are very different pathologies. But, they have much more in common than it might seem at first glance. In this review, the authors propose to consider these brain pathologies from the point of view of the unity of their pathogenetic mechanisms and approaches to therapy. Particular attention is paid to promising therapeutic approaches, such as therapy using cells and their secretion products: an analysis of the accumulated experimental data, the advantages and limitations of these approaches in the treatment of brain damage was carried out. The review may be of interest both to specialists in the field of neurology, neurosurgery and neurorehabilitation, and to readers who want to learn more about the progress of regenerative biomedicine in the treatment of brain pathologies.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"124 3. Vyp. 2","pages":"83-91"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140177983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Associations between components of metabolic syndrome and cognitive impairment in patients with schizophrenia].","authors":"E G Kornetova, S A Galkin, I A Mednova, V V Tsiguntsev, A S Boiko, A N Kornetov, S A Ivanova, N A Bokhan","doi":"10.17116/jnevro202412403182","DOIUrl":"10.17116/jnevro202412403182","url":null,"abstract":"<p><strong>Objective: </strong>To study the relationship between the individual components of the metabolic syndrome and cognitive dysfunction in patients with schizophrenia.</p><p><strong>Material and methods: </strong>A total of 133 patients with schizophrenia were examined. To assess cognitive functioning, the Brief Assessment of Cognition in Schizophrenia (BACS) was used. The components of the metabolic syndrome were determined in accordance with the criteria of the International Diabetes Federation.</p><p><strong>Results: </strong>Hyperglycemia in patients with schizophrenia led to a decrease in cognitive functioning in two domains: verbal fluency (β=-10.67; <i>p</i>=0.019) and attention stability (β=-9.519; <i>p</i>=0.043). Abdominal obesity was associated with lower indicators of executive functions (β=-8.856; <i>p</i>=0.026).</p><p><strong>Conclusion: </strong>It is assumed that drug treatment of some components of the metabolic syndrome may affect cognitive functions in patients with schizophrenia.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"124 3","pages":"82-87"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140289749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Neurometabolic therapy of mild cognitive impairment in patients with chronic cerebral ischemia].","authors":"E A Antipenko, A V Shulyndin, K M Belyakov","doi":"10.17116/jnevro202412403142","DOIUrl":"10.17116/jnevro202412403142","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effect of a sequential therapy regimen with Mexidol (500 mg injections intravenously for 14 days) and Mexidol FORTE 250 (250 mg tablets 3 times a day for 60 days) on higher cortical functions in patients with moderate cognitive disorders in chronic cerebral ischemia.</p><p><strong>Material and methods: </strong>A comparative, prospective study included 63 patients with chronic cerebral ischemia with moderate cognitive impairment. All patients received basic therapy aimed at reducing risk factors (antihypertensive, antithrombotic drugs as indicated). Patients of the main group (30 people: 12 men, 18 women) received Mexidol intravenously 500 mg in 100 ml of 0.9% NaCl solution once a day for 14 days, then Mexidol FORTE 250 (film-coated tablets) 250 mg 3 times a day for the next 60 days. The comparison group consisted of 33 patients (14 men, 19 women) who received only basic therapy. The groups were comparable in terms of age, sex characteristics and severity of cognitive deficit. We examined cognitive status (MoCA scale, Frontal Dysfunction Battery, 10 Word Memorization tests), severity of asthenia (MFI-20 scale), anxiety and depression (HADS scale), patient's subjective assessment of the dynamics of the condition (CGI-improvement scale) in 1st, 14th and 74th±5 days of observation. On days 1 and 74±5 of observation, patients were examined using transcranial magnetic stimulation to study the neuronal activity of the cerebral cortex.</p><p><strong>Results: </strong>In the main group, at the time of completion of taking Mexidol and Mexidol FORTE 250, a pronounced cognitive regression was noted (MoCA scale +3 points, difference with the comparison group 1 point (<i>p</i><0.0001); Frontal Dysfunction Battery test +4 points, difference with comparison group 2 points (<i>p</i><0.001); memory test «10 words» +2 points, difference with the comparison group 1 point (<i>p</i><0.05), emotional (HADS anxiety scale -8 points, difference with the comparison group 3 points (<i>p</i><0.001), depression -3.5 points, difference with the comparison group 1.5 points (<i>p</i><0.01), asthenic disorders (MFI-20 scale -30 points, difference with the comparison group 15.5 points (<i>p</i><0.01), improvement in the well-being of patients (CGI-improvement scale -2 points, difference with the comparison group 1 point (<i>p</i><0.0001). According to the transcranial magnetic stimulation performed, a statistically significant decrease in the central motor conduction time at the level of 1 and 2 motor neurons of the pyramidal tract bilaterally from the start to the end of therapy with Mexidol and Mexidol FORTE 250 was determined (<i>p</i><0.01). An inverse correlation was found between the time of central motor conduction and the results of the Frontal Dysfunction Battery test at the same time points with left-sided localization of 1 motor neuron (<i>p</i><0.01). The results of a study of the use of sequential therapy with Mexidol 50","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"124 3","pages":"42-51"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140289782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Validation of screening method based on EEG analysis for the risk assessment of psychiatric and behavioral disorders: a pilot study].","authors":"I V Kichuk, N V Solovieva, A A Keskinov, V S Yudin, K V Golanova, N A Chuprova, M N Rusalova, A K Tikhonov, S V Chausova, N B Nogai, A A Mitrofanov","doi":"10.17116/jnevro202412403188","DOIUrl":"10.17116/jnevro202412403188","url":null,"abstract":"<p><strong>Objective: </strong>To assess the validity of the screening method based on EEG analysis using predictive analytics algorithms with the calculation of linear discriminant functions (LDFs), in comparison with a classification system based on psychometric self-report scales.</p><p><strong>Material and methods: </strong>A comparative cross-sectional study with partial blinding involving healthy volunteers was conducted at two investigational sites. The calculated scores of LDFs used to assess risks of impulsivity, depression and anxiety acted as quantitative characteristics of subjects' mental state. Testing included completing psychometric scales.</p><p><strong>Results: </strong>As a result of the performed validation of the original screening method based on EEG analysis in comparison with the scores of psychometric scales chosen as a reference method, satisfactory results were obtained with the best parameters of sensitivity, specificity, and accuracy for detecting high levels of impulsivity associated with pronounced aggressiveness. Of considerable interest is also the direct correlation found between high levels of LDF impulsivity scores and high levels of self-rated aggression on a psychometric scale (BPAQ-24).</p><p><strong>Conclusion: </strong>The results open up the possibility of using the proposed method to predict a number of emotional and behavioral characteristics of subjects, including a high risk of aggressive behavior as part of professional selection.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"124 3","pages":"88-96"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140289787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}